Singapore markets closed
  • Straits Times Index

    3,041.29
    -79.29 (-2.54%)
     
  • S&P 500

    4,655.27
    +60.65 (+1.32%)
     
  • Dow

    35,135.94
    +236.60 (+0.68%)
     
  • Nasdaq

    15,782.83
    +291.18 (+1.88%)
     
  • BTC-USD

    57,861.12
    +830.96 (+1.46%)
     
  • CMC Crypto 200

    1,466.18
    +37.25 (+2.61%)
     
  • FTSE 100

    7,051.36
    -58.59 (-0.82%)
     
  • Gold

    1,794.40
    +9.20 (+0.52%)
     
  • Crude Oil

    67.96
    -1.99 (-2.84%)
     
  • 10-Yr Bond

    1.5300
    0.0000 (0.00%)
     
  • Nikkei

    27,821.76
    -462.16 (-1.63%)
     
  • Hang Seng

    23,475.26
    -376.98 (-1.58%)
     
  • FTSE Bursa Malaysia

    1,513.98
    +3.41 (+0.23%)
     
  • Jakarta Composite Index

    6,533.93
    -74.36 (-1.13%)
     
  • PSE Index

    7,200.88
    -77.56 (-1.07%)
     

What Type Of Shareholders Make Up Galera Therapeutics, Inc.'s (NASDAQ:GRTX) Share Registry?

  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Galera Therapeutics, Inc. (NASDAQ:GRTX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned.

Galera Therapeutics is a smaller company with a market capitalization of US$207m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. We can zoom in on the different ownership groups, to learn more about Galera Therapeutics.

Check out our latest analysis for Galera Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Galera Therapeutics?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

Galera Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Galera Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

It would appear that 5.7% of Galera Therapeutics shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Our data shows that New Enterprise Associates, Inc. is the largest shareholder with 17% of shares outstanding. With 12% and 9.4% of the shares outstanding respectively, Sofinnova Investment, Inc. and Novartis Venture Funds are the second and third largest shareholders. Furthermore, CEO J. Sorensen is the owner of 0.9% of the company's shares.

On looking further, we found that 55% of the shares are owned by the top 5 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Galera Therapeutics

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

We can see that insiders own shares in Galera Therapeutics, Inc.. In their own names, insiders own US$2.8m worth of stock in the US$207m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.

General Public Ownership

The general public, with a 12% stake in the company, will not easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With a stake of 61%, private equity firms could influence the Galera Therapeutics board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Galera Therapeutics is showing 6 warning signs in our investment analysis , and 3 of those are potentially serious...

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting